PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
AboutPricing
Drug ReportsMecasermin rinfabate
Mecasermin rinfabate
Increlex, Iplex (mecasermin rinfabate) is a protein pharmaceutical. Mecasermin rinfabate was first approved as Iplex on 2005-12-12. It has been approved in Europe to treat laron syndrome.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Plot placeholder
Mock data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
musculoskeletal diseasesD009140
hereditary congenital and neonatal diseases and abnormalitiesD009358
endocrine system diseasesD004700
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
Reference product - 351(a)
Reference product - 351(a)
Interchangeable product - 351(k)
Interchangeable product - 351(k)
Biosimilar product - 351(k)
Biosimilar product - 351(k)
Mecasermin rinfabate
Tradename
Proper name
Company
Number
Date
Products
Iplexmecasermin rinfabateInsmedN-21884 DISCN2005-12-12
1 products
Hide discontinued
Labels
FDA
EMA
No data
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
Expiration
Code
mecasermin rinfabate, Iplex, Insmed Incorporated
2112-12-12Orphan excl.
Patent Expiration
No data
ATC Codes
H: Systemic hormonal preparations, excl. sex hormones and insulins
H01: Pituitary and hypothalamic hormones and analogues
H01A: Anterior pituitary lobe hormones and analogues
H01AC: Somatropin and somatropin agonists
H01AC05: Mecasermin rinfabate
HCPCS
No data
Clinical
Clinical Trials
244 clinical trials
View more details
Plot placeholder
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
AcromegalyD0001723861128
Laron syndromeD046150Orphanet_633E34.3212634417
DwarfismD004392E34.311422411
Pituitary dwarfismD004393EFO_1001109E23.0143411
Failure to thriveD005183112126
Cognitive dysfunctionD060825G31.84145
Heart failureD006333EFO_0003144I5012125
Wounds and injuriesD014947T14.81135
Endocrine system diseasesD004700EFO_0001379E34.921115
Chronic kidney failureD007676EFO_0003884N18.6224
Show 24 more
Indications Phases 3
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
NeoplasmsD009369C8053310
OsteoporosisD010024EFO_0003882M81.01134
SarcomaD012509224
Insulin resistanceD007333EFO_0002614E88.8192214
Rectal neoplasmsD01200433
Healthy volunteers/patients123
Liver neoplasmsD008113EFO_1001513C22.0213
Chromosome disordersD025063EFO_0003831Q99.933
Chromosome deletionD00287233
Retinopathy of prematurityD012178EFO_1001158H35.133
Show 71 more
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Cystic fibrosisD003550EFO_0000390E84213
Colorectal neoplasmsD015179112
AgingD000375GO_0007568R41.81112
GliomaD005910EFO_000052011
Brain stem neoplasmsD020295EFO_100176711
PinealomaD01087111
Squamous cell carcinoma of head and neckD00007719511
Joint instabilityD00759311
TendinopathyD052256EFO_1001434M77.911
HypersensitivityD006967EFO_0003785T78.4011
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Metabolic bone diseasesD00185133
Alzheimer diseaseD000544EFO_0000249F0322
Bone fracturesD050723EFO_0003931T14.822
Igg deficiencyD017099D80.322
SchizophreniaD012559EFO_0000692F2022
StrokeD020521EFO_0000712I63.922
Macular degenerationD008268EFO_0001365H35.3011
Parkinson diseaseD010300EFO_0002508G2011
AnemiaD000740EFO_0004272D64.911
Vascular dementiaD015140F0111
Show 95 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameMecasermin rinfabate
INNmecasermin rinfabate
Description
Mecasermin rinfabate (INN, USAN) (brand name Iplex), also known as rhIGF-1/rhIGFBP-3, is a drug consisting of recombinant human insulin-like growth factor 1 (IGF-1) and recombinant human insulin-like growth factor binding protein-3 (IGFBP-3) which is used for the treatment of amyotrophic lateral sclerosis (Lou Gehrig's disease).
Classification
Protein
Drug classgrowth factors: insulin-like growth factors
Image (chem structure or protein)Loading
Structure (InChI/SMILES or Protein Sequence)
Identifiers
PDB
CAS-ID
RxCUI
ChEMBL IDCHEMBL1201717
ChEBI ID
PubChem CID
DrugBank
UNII IDNZ8M50KKRG (ChemIDplus, GSRS)
Target
No data
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Plot placeholder
Mock data
Subscribe for the real data
Additional graphs summarizing 4,976 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Plot placeholder
Mock data
Subscribe for the real data
803 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use